Market Overview

Tekmira Up 6% On Leerink Initiation

Related TKMR
Tekmira Officially Becomes Arbutus Biopharma
5 Biotech Stocks On Deck With The FDA

Shares of Tekmira Pharmaceuticals (NASDAQ: TKMR) are up six percent in Monday’s pre-market trading following commentary by Leerink partners.

Leerink initiated coverage at Outperform and assigned a $25 price target.

Monday’s rally follows a 50 percent peak to trough selloff last week and 10 percent climb Friday.

Shares of Tekmira were last trading at $19.25, up 6.47 percent.

Latest Ratings for TKMR

Jun 2015Maxim GroupDowngradesBuyHold
Jun 2015Maxim GroupDowngradesHold
Nov 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for TKMR
View the Latest Analyst Ratings

Posted-In: LeerinkPrice Target Initiation Analyst Ratings Movers


Related Articles (TKMR)

View Comments and Join the Discussion!